SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
NCT04907214
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class
Conditions
Obesity
Pre-diabetes
Interventions
DRUG:
Empagliflozin 25 MG
Sponsor
Vanderbilt University Medical Center